Deborah DiSanzo - Astrazeneca Plc Non-Executive Independent Director

AZN -  USA Stock  

USD 57.64  0.83  1.46%

  Director
Ms. Deborah DiSanzo serves as NonExecutive Independent Director of the Company effective 1 December 2017. She is a Harvard University Advanced Leadership Fellow. Prior to this, she served as General Manager for IBM Watson Health, the IBM business unit founded to advance AI in health. Deborah has a distinguished career working at the intersection of healthcare and technology. Prior to IBM, she was CEO of Philips Healthcare, having previously held executive roles at Agilent and HewlettPackard. Deborah was honoured by multiple organisations as a top health influencer including Health Data Management, who named her as one of the top 20 people to watch in healthcare IT, and Modern Healthcare, who list her as a Top 25 Women in Healthcare. She is the recipient of Xconomys X of the Year Award as a Tech and Health Connector. Babson College recognised Deborahs impact in the world as one of the institutions leading entrepreneurial alumni leaders. Deborah earned an MBA from Babson College and a BS from Merrimack College. Deborah is a Harvard University Advanced Leadership Fellow.
Age: 59  Director Since 2017  MBA    
(44) 1223 352 858  www.astrazeneca.com

Astrazeneca Plc Management Efficiency

Astrazeneca Plc ADR has Return on Asset of 4.19 % which means that on every $100 spent on asset, it made $4.19 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 29.67 %, implying that it generated $29.67 on every 100 dollars invested. Astrazeneca Plc management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Astrazeneca Plc Return on Investment is quite stable at the moment as compared to the past year. The company's current value of Return on Investment is estimated at 15.99. Return on Average Assets is expected to rise to 0.06 this year, although the value of Return on Average Equity will most likely fall to 0.22. Astrazeneca Plc Average Assets are quite stable at the moment as compared to the past year. The company's current value of Average Assets is estimated at 66.33 Billion
The company has 22.49 B in debt with debt to equity (D/E) ratio of 1.56, which is OK given its current industry classification. Astrazeneca Plc ADR has a current ratio of 0.85, suggesting that it has not enough short term capital to pay financial commitments when the payables are due.
The market value of Astrazeneca Plc ADR is measured differently than its book value, which is the value of Astrazeneca that is recorded on the company's balance sheet. Investors also form their own opinion of Astrazeneca Plc's value that differs from its market value or its book value, called intrinsic value, which is Astrazeneca Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Astrazeneca Plc's market value can be influenced by many factors that don't directly affect Astrazeneca Plc ADR underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Astrazeneca Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine Astrazeneca Plc value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Astrazeneca Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Similar Executives

Found 9 records

DIRECTOR Since

Michael GreyHorizon Therapeutics
2012
Jeffrey HimawanHorizon Therapeutics
2007
James ShannonHorizon Therapeutics
2017
Pascale WitzHorizon Therapeutics
2017
William DanielHorizon Therapeutics
2014
Gino SantiniHorizon Therapeutics
2012
Thomas WatkinsHorizon Therapeutics
2014
Ronald PauliHorizon Therapeutics
2011
Virinder NohriaHorizon Therapeutics
2014
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca Plc operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 76100 people. Astrazeneca Plc ADR (AZN) is traded on NASDAQ Exchange in USA. It is located in 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom and employs 76,100 people. Astrazeneca Plc is listed under Pharmaceutical Products category by Fama And French industry classification.

Astrazeneca Plc ADR Leadership Team

Elected by the shareholders, the Astrazeneca Plc's board of directors comprises two types of representatives: Astrazeneca Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Astrazeneca. The board's role is to monitor Astrazeneca Plc's management team and ensure that shareholders' interests are well served. Astrazeneca Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Astrazeneca Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Marc Dunoyer, Chief Financial Officer, Executive Director
Sherilyn McCoy, Non-Executive Independent Director
Genevieve Berger, Non-Executive Independent Director
Luke Miels, Executive Vice-President GPPS
Sean Bohen, Chief Medical Officer, Executive Vice President - Global Medicines Development
Paul Hudson, Executive Vice President North America
Nazneen Rahman, Non-Executive Independent Director
Jose Baselga, Executive Vice President - Research & Development Oncology
JeanPhilippe Courtois, Non-Executive Independent Director
Deborah Eldracher, Non-Executive Independent Director
Thomas Larsen, IR Contact Officer
Katarina Ageborg, Executive Vice President - Sustainability, Chief Compliance Officer
Tony Mok, Non-Executive Independent Director
Mark Mallon, Executive Vice President International
Fiona Cicconi, Executive Vice President - Human Resources
Deborah DiSanzo, Non-Executive Independent Director
Shriti Vadera, Non-Executive Independent Director
Leif Johansson, Non-Executive Independent Chairman of the Board
Leon Wang, Executive Vice President - International and China President
Ann Cairns, Non-Executive Director
Adrian Kemp, Company Secretary
Cornelia Bargmann, Non-Executive Director
Tim JacksonSmith, Non-Executive Director
Michel Demare, Non-Executive Independent Director
Graham Chipchase, Senior Non-Executive Independent Director
David Smith, Executive VP of Operations and Information Services
Pascal Soriot, CEO, Executive Director and Member of Disclosure Committee
Pam Cheng, Executive Vice-President of Operations and Information Technology
Baroness Vadera, Non-Executive Independent Director
Philip Broadley, Non-Executive Independent Director
Narayan Seshadri, Independent Director
Jeffrey Pott, General Counsel
Ruud Dobber, Executive Vice President, BioPharmaceuticals Business
David Fredrickson, Executive Vice-President Global Head Oncology Business Unit
Bahija Jallal, Executive Vice President MedImmune
Rudolph Markham, Non-Executive Independent Director
Menelas Pangalos, Executive Vice President - Research & Development BioPharmaceuticals
Weiying Wang, Non-Executive Director
Bruce Burlington, Non-Executive Independent Director
Marcus Wallenberg, Non-Executive Director
Iskra Reic, Executive Vice President - Europe and Canada

Astrazeneca Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Astrazeneca Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Astrazeneca Plc Investors Sentiment

The influence of Astrazeneca Plc's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Astrazeneca. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - AZN

Astrazeneca Plc ADR Investor Sentiment

Predominant part of Macroaxis users are presently bullish on Astrazeneca Plc ADR. What is your sentiment towards investing in Astrazeneca Plc ADR? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Pair Trading with Astrazeneca Plc

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Astrazeneca Plc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Astrazeneca Plc will appreciate offsetting losses from the drop in the long position's value.

Astrazeneca Plc Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Astrazeneca Plc and Horizon Therapeutics. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Trending Equities. Note that the Astrazeneca Plc ADR information on this page should be used as a complementary analysis to other Astrazeneca Plc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for Astrazeneca Stock analysis

When running Astrazeneca Plc ADR price analysis, check to measure Astrazeneca Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astrazeneca Plc is operating at the current time. Most of Astrazeneca Plc's value examination focuses on studying past and present price action to predict the probability of Astrazeneca Plc's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Astrazeneca Plc's price. Additionally, you may evaluate how the addition of Astrazeneca Plc to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
The market value of Astrazeneca Plc ADR is measured differently than its book value, which is the value of Astrazeneca that is recorded on the company's balance sheet. Investors also form their own opinion of Astrazeneca Plc's value that differs from its market value or its book value, called intrinsic value, which is Astrazeneca Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Astrazeneca Plc's market value can be influenced by many factors that don't directly affect Astrazeneca Plc ADR underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Astrazeneca Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine Astrazeneca Plc value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Astrazeneca Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.